Penumbra (NYSE:PEN) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen downgraded shares of Penumbra (NYSE:PEN) from a buy rating to a hold rating in a report released on Saturday morning.

A number of other brokerages have also commented on PEN. JPMorgan Chase & Co. upgraded shares of Penumbra from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $275.00 to $370.00 in a report on Thursday, December 18th. Needham & Company LLC downgraded Penumbra from a “buy” rating to a “hold” rating in a research report on Friday. Truist Financial lowered shares of Penumbra from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $370.00 to $374.00 in a research note on Friday. Piper Sandler cut shares of Penumbra from an “overweight” rating to a “hold” rating and set a $374.00 price objective for the company. in a research report on Thursday. Finally, Wells Fargo & Company reissued an “equal weight” rating and set a $374.00 price target on shares of Penumbra in a report on Thursday. Seven research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Penumbra has an average rating of “Hold” and an average target price of $355.88.

Penumbra Price Performance

Penumbra stock opened at $350.93 on Friday. Penumbra has a 52 week low of $221.26 and a 52 week high of $352.15. The business’s fifty day moving average is $303.54 and its two-hundred day moving average is $269.65. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 6.73. The firm has a market cap of $13.74 billion, a P/E ratio of 83.95, a P/E/G ratio of 2.14 and a beta of 0.71.

Penumbra (NYSE:PEN) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.07. The business had revenue of $354.69 million for the quarter, compared to analysts’ expectations of $340.77 million. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.The firm’s quarterly revenue was up 17.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.85 earnings per share. Equities research analysts forecast that Penumbra will post 3.67 earnings per share for the current fiscal year.

Insider Activity at Penumbra

In other Penumbra news, Director Thomas Wilder sold 186 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $310.72, for a total value of $57,793.92. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Harpreet Grewal sold 186 shares of the company’s stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $227.58, for a total transaction of $42,329.88. Following the transaction, the director owned 8,516 shares in the company, valued at approximately $1,938,071.28. The trade was a 2.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 34,144 shares of company stock worth $10,260,127 over the last quarter. Company insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Penumbra

Several institutional investors have recently bought and sold shares of PEN. Machina Capital S.A.S. bought a new position in shares of Penumbra during the 2nd quarter valued at about $369,000. First Trust Advisors LP increased its holdings in Penumbra by 4.0% during the 2nd quarter. First Trust Advisors LP now owns 100,723 shares of the company’s stock valued at $25,849,000 after purchasing an additional 3,906 shares during the period. Russell Investments Group Ltd. boosted its holdings in Penumbra by 22.9% in the second quarter. Russell Investments Group Ltd. now owns 26,604 shares of the company’s stock valued at $6,827,000 after acquiring an additional 4,960 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in Penumbra by 716.5% in the second quarter. Janney Montgomery Scott LLC now owns 24,749 shares of the company’s stock worth $6,351,000 after buying an additional 21,718 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in shares of Penumbra by 340.0% during the second quarter. Marshall Wace LLP now owns 82,031 shares of the company’s stock valued at $21,052,000 after purchasing an additional 63,389 shares in the last quarter. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Trending Headlines about Penumbra

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: Boston Scientific agreed to acquire Penumbra for $374 per share in a cash-and-stock deal, citing strategic expansion into mechanical thrombectomy and neurovascular markets — the transaction creates a significant takeover premium that lifted investor interest. Boston Scientific announces agreement to acquire Penumbra, Inc.
• Positive Sentiment: Penumbra issued preliminary Q4 and FY2025 results/guidance showing higher-than-consensus Q4 revenue guidance (~$383.0M–$384.8M vs. $361.9M consensus) and FY revenue around $1.4B — these operational beats support the deal valuation and the company’s growth profile. Penumbra provides preliminary update on Q4 and FY2025 results
• Neutral Sentiment: Wells Fargo cut its rating to Equal Weight but left a $374 price target — the target essentially aligns with the deal price, implying limited upside beyond the acquisition terms unless a competing bid emerges. Penumbra downgraded at Wells Fargo
• Neutral Sentiment: Market commentary and earnings-estimate revisions note strong recent volume and a large one-day surge; analysts point to momentum but caution on sustainability absent competing bids or further fundamentals. Zacks coverage of Penumbra price move
• Negative Sentiment: Needham downgraded Penumbra from Buy to Hold — a straightforward analyst reaction that could weigh on sentiment and aftermarket buying absent a higher competing bid. Penumbra downgraded at Needham
• Negative Sentiment: Multiple shareholder law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Brodsky & Smith, others) have opened investigations and class-action alerts alleging the sale price/process may be unfair — litigation or legal challenges could delay the deal, lead to renegotiation, or increase transaction costs. Kahn Swick & Foti investor alert on Penumbra sale

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.